NCT04260802终止1 期
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 73
- 试验地点
- 5
- 主要终点
- Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a
研究概览
简要总结
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Criteria: Inclusion Criteria:
- •1. Have histological or cytological evidence of a diagnosis of selected cancer types that is locally advanced and/or metastatic
- •Have the presence of evaluable disease for the Phase 1b Monotherapy
- •Have the presence of evaluable and measurable disease for the Phase 1b combination part and the Phase 2a part of the study.
- •The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their disease or patients who have refused standard treatments.
- •2. Cancer treatment and type criteria:
- •Have received at least 1 but no more than 4 prior systemic therapies for locally advanced or metastatic disease (e.g., hormonal, cytotoxic, etc.) for the following cancer types, for Phase 1b:
- •Triple Negative Breast Cancer (TNBC): Must have recurrent/refractory TNBC, defined as any breast cancer that expresses less than (˂)1% estrogen receptor (ER), ˂ 1% progesterone receptor (PR), and is Human Epidermal Growth Factor Receptor 2 (Her2) negative. Must have failed at least one chemotherapy regimen.
- •Gastric Cancer: Must have failed a platinum-containing chemotherapy regime.
- •Cervical Cancer: Must have failed at least one chemotherapy regimen.
- •Ovarian Cancer: Must have failed a platinum-containing chemotherapy regimen but not be platinum refractory.
- •Hepatocellular Cell Carcinoma (HCC): May have failed unlimited liver local therapies.
- •Sarcoma: Must have failed at least one prior chemotherapy regimen.
- •Squamous Cell Carcinoma of Head and Neck (SCCHN): Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor.
- •Bladder Cancer: Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor.
- •Non Small Cell Lung Cancer (NSCLC): Must have failed a platinum-containing chemotherapy regimen or Immuno Oncology (IO) agent in the first line. Must have failed a previous immune checkpoint inhibitor. Must not have any history of tumors that test positive for epidermal growth factor receptor (EGFR), Receptor Tyrosine Kinase (ROS1), Anaplastic Lymphoma Kinase (ALK) mutations or ALK fusions or any other mutations for which tyrosine kinase inhibitors are available.
- •Renal Cell Carcinoma (RCC): Must have failed at least one prior systemic therapy. Must have failed a previous IO agent.
- •Urothelial Cancer: Must have failed at least one prior systemic therapy. Must have failed a previous IO agent.
- •Merkel Cell: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent.
- •Squamous Cell Carcinoma of the Skin: Must have failed at least 1 prior systemic therapy for advanced disease and may have failed a previous IO agent.
- •3. Phase 1b - combination dose escalation:
- •Cervical Cancer Must have failed at least 1 chemotherapy regimen.
- •Bladder Cancer Must have failed a platinum-containing chemotherapy regimen. Must have failed a previous immune checkpoint inhibitor.
- •RCC Must have failed at least 1 prior systemic therapy. Must have failed a previous IO agent.
- •Urothelial cancer Must have failed at least 1 prior systemic therapy. Must have failed a previous IO agent.
- •Diffuse large B cell lymphoma Must have failed prior rituximab therapy. May have failed prior chemotherapy or other IO agents.
- •NSCLC Must have failed a single agent PD-1 or PD-L1 inhibitor as the last regimen and must have responded to the agent.
- •Must not have any history of tumors that test positive for EGFR, ROS1, ALK mutations or ALK fusions, or any other mutations for which tyrosine kinase inhibitors are available or are under development.
- •4. For Phase 2a: Must have histological or cytological confirmation of a solid tumor that is locally advanced or metastatic. At least two cancer type will be selected amongst the ones evaluated in the Phase 1b combination dose escalation part of the study.
- •5. Have adequate organ function 6 Have a performance status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale 7 Have discontinued cytotoxic therapy, biologic therapy, immunotherapy, radiotherapy, and cancer-related hormonal therapy at least 21 days prior to study enrollment
- •Are recovered or recovering from the acute adverse effects of any chemotherapy, biologic, therapy, immunotherapy, cancer-related hormonal therapy, or radiotherapy
- •Patients who have had major surgery must be fully recovered and greater than (≥)4 weeks post-operative
- •Men with partners of child-bearing potential or women with child-bearing potential must agree to use a medically approved contraceptive method during and for at least 12 weeks following the last dose of study drug (e.g., intrauterine device (IUD), birth control pills, or barrier method)
- •Women of child-bearing potential must have a negative serum pregnancy test documented
- •Have an estimated life expectancy of at least 3 months
排除标准
- •Have symptomatic central nervous system (CNS) metastasis. Patients with treated CNS metastases are eligible for this study if they are asymptomatic and off of corticosteroids for a minimum of 7 days. Patients with primary brain tumors are not eligible
- •Have a history of major organ transplant (e.g., heart, lungs, liver, and kidney) or an autologous or allogeneic hematopoietic stem cell transplant
- •Females who are pregnant or nursing
- •Have known, symptomatic acquired immuno deficiency syndrome (AIDS) or active hepatitis A, B or C
- •Previous treatment-related, severe (≥Grade 3) Adverse Event (AE) or any neurologic or ocular AE while receiving an IO agent
- •Active or prior documented autoimmune disease within the past 2 years Patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are eligible
- •Active or prior documented inflammatory bowel disease
- •History of tuberculosis, interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required corticosteroid therapy
- •Receipt of live attenuated vaccination within 28 days prior
- •Current or prior use of immunosuppressive medication within 28 days prior
- •Are currently enrolled in another clinical study of an investigational medicinal product
- •Have a second primary malignancy that may affect the interpretation of results
- •Are unwilling or unable to participate in, or do not have tissue adequate for a tumor biopsy
研究组 & 干预措施
Drug: Phase 1b: Dose Escalation (monotherapy)
Experimental
Escalating doses of OC-001 administered intravenously (IV)
Drug: Phase 1b Dose: Escalation (Combination therapy)
Experimental
Escalating doses of OC-001 administered by IV in combination Avelumab.
干预措施: Drug: OC-001 in Combination with Avelumab (Drug)
Drug: Phase 2a
Experimental
Doses of OC-001 administered by IV in combination with Avelumab b)
干预措施: Drug: OC-001 in Combination with Avelumab (Drug)
结局指标
主要结局
Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a
时间窗: Baseline up to two years
Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event in Phase 2a
Number of participants with a Dose Limiting Toxicity (DLT) in Phase 1b
时间窗: Baseline through Cycle 1 (Day 28)
A Dose-Limiting Toxicity (DLT) is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the criteria identified in the Common Terminology Criteria for Adverse Events (CTCAE, Version 5)
次要结局
- Maximum Observed OC-001 Concentration (Cmax) in Phase 2a(Baseline through 12 weeks)
- Area Under the OC-001 Plasma Concentration Time Curve (AUC) in Phase 1b(Baseline through 12 weeks)
- Overall Response Rate (ORR) in Phase 2a(Baseline up to two years)
- Maximum Observed OC-001 Concentration (Cmax) in Phase 1b(Baseline through 12 weeks)
- Time to reach OC-001 Cmax (Tmax) in Phase 1b(Baseline through 12 weeks)
- Minimum Observed OC-001 Concentration (Cmin) in Phase 1b(Baseline through 12 weeks)
- Duration of Response (DOR) in Phase 2a(Baseline up to two years)
- Time to Response (TTR) in Phase 2a(Baseline up to two years)
- Progression Free Survival (PFS) in Phase 2a(Baseline up to two years)
- One-Year Survival Rate in Phase 2a(Baseline up to two years)
- Minimum Observed OC-001 Concentration (Cmin) in Phase 2a(Baseline through 12 weeks)
- Trough drug concentration of OC-001 (Ctrough) in Phase 2a(Baseline through 12 weeks)
- Disease Control Rate (DCR) in Phase 2a(Baseline up to two years)
- Overall Survival (OS) in Phase 2a(Baseline up to two years)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid LeukemiaLeukemia, Myeloid, AcuteNCT04150887OncoVerity, Inc.61
已完成
1 期
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue SarcomaSoft Tissue SarcomaNCT03126591Eli Lilly and Company41
进行中（未招募）
1 期
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerOvarian Cancer by FIGO StageOvarian Cancer Stage IIIOvarian Cancer Stage IVNCT04938583CanariaBio Inc.54
进行中（未招募）
3 期
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisMultiple SclerosisNCT05269004Hoffmann-La Roche1,300
终止
1 期
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT02953561M.D. Anderson Cancer Center19